GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
1 report, 1 independent
Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- GSK is seeking priority review for its Jemperli application, and the FDA set the PDUFA action date.Sub-event
GSK secured FDA clearance for a lung cancer medicine, adding to its portfolio.1 source
Keep exploring
The entities involved
Related events
- GSK announced positive results for lung cancer drugs. Separately, Andy Burnham is meeting executives to discuss growth plans, while oil prices rose due to strikes on Saudi infrastructure.
- Experimental therapies require approval from the FDA.
- Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
- The FDA recommended advancement for a new drug application submitted by a company.